Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
| ▸ | GBA1 | P04062 | 4/20 | 0.50 |
| ▸ | MGAM | O43451 | 6/20 | 0.33 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Scyllitol SCHEMBL12411898 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL6378921 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL4447990 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL4438767 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL12377889 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL21388397 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL5969 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL188237 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL188106 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| SCHEMBL1963355 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694699-A2 | COMPOSITIONS AND METHODS OF CONTROLLING MAMMALIAN SATIETY | VitaKey Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| WO-2024216228-A2 | COMPOSITIONS AND METHODS OF CONTROLLING MAMMALIAN SATIETY | VITAKEY INC. (US) | 2024-10-17 | — | — | WO | claimed |
| CN-115627505-B | Pulse cyanide-free gold electroplating liquid and electroplating process thereof | 深圳创智芯联科技股份有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-115627505-A | Pulse cyanide-free gold electroplating solution and electroplating process thereof | 深圳创智芯联科技股份有限公司 | 2023-01-20 | — | — | CN | claimed |
| US-7758150-B2 | Capture member and ink jet printer | SEIKO EPSON CORPORATION (JP) | 2010-07-20 | — | — | US | claimed |
| EP-1000541-B1 | Defined serumfree medical solution for ophthalmology | SKELNIK DEBRA L (US) | 2004-01-14 | — | — | EP | claimed |
| CN-1122030-C | Process for synthesis of inositol phosphates | RES FUNDATION OF NEWYORK UNIV (US) | 2003-09-24 | — | — | CN | claimed |
| US-6153582-A | USED FOR PRESERVATION AND ENHANCEMENT OF HUMAN CORNEAL TISSUE, SPECIFIED AS THE TIME BETWEEN REMOVAL FROM THE DONOR AND TRANSPLANTATION | BAUSCH & LOMB SURGICAL, INC. (US) | 2000-11-28 | — | — | US | claimed |
| CN-1265105-A | Novel synthesis of myo-inositol phosphates | RES FUNDATION OF NEWYORK UNIV (US) | 2000-08-30 | — | — | CN | claimed |
| EP-1000541-A1 | Defined serumfree medical solution for ophthalmology | Bausch & Lomb Surgical, Inc. (US) | 2000-05-17 | — | — | EP | claimed |
| JP-3027339-A | — | — | None | — | — | JP | disclosed |
| JP-61263902-A | — | — | None | — | — | JP | disclosed |
| CN-122080223-A | Multi-specific binding proteins for cancer treatment | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260071177-A1 | ACCELERATION OF STEM CELL DIFFERENTIATION | UNIV MINNESOTA (US) | 2026-03-12 | — | — | US | disclosed |
| US-12571042-B2 | Markers specific for pluripotent stem cells, and methods of using the same | FUJIFILM CORPORATION (JP) | 2026-03-10 | — | — | US | disclosed |
| US-3976768-A | ANTIBIOTIC | ABBOTT LABORATORIES (US) | 1976-08-24 | — | — | US | disclosed |
| US-3974035-A | CULTURES | MEIJI SEIKA KAISHA, LTD. (JA) | 1976-08-10 | — | — | US | disclosed |
| US-3956068-A | AMINOGLYCOSIDES | SCHERING CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
| US-RE28700-E | STREPTOMYCES | HOFFMANN-LA ROCHE INC. (US) | 1976-01-27 | — | — | US | disclosed |
| US-3931400-A | CULTIVATION OF MICROMONOSPORA, ANTIBIOTIC | ABBOTT LABORATORIES (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071177-A1 | ACCELERATION OF STEM CELL DIFFERENTIATION | FGFR2, FGF2, FGF1 | LMNA 2877/4885APP 2418/4885GBA1 4662/4885 |
| US-12571042-B2 | Markers specific for pluripotent stem cells, and methods of using the same | DNMT3L, POU2F1, POU2F2 | LMNA 1948/4885APP 2159/4885GBA1 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.